Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#1370 68Ga-DOTATOC PET and Gene Expression Profile in Patients with Neuroendocrine Carcinomas
Introduction: Somatostatin receptor expression on both protein and gene expression levels were compared with in vivo 68Ga-DOTATOC PET/CT in patients with neuroendocrine carcinomas (NEC).
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Olsen I
Authors: Olsen I, Langer S, Federspiel B, Oxbøl J, Loft A,
Keywords: neuroendocrine carcinoma, gene expression, 68Ga-DOTATOC, IHC, SSTR2,
Introduction: Data on G3-NET and NEC are limited. No standard therapy following platinum-etoposide failure is established and first-line therapy in G3-NET is not codified.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Heetfeld M, Rinke A, Borbath I, Crespo G, Olsen I,
Keywords: gastrointestinal cancer, neuroendocrine carcinoma, grade 3 NET, Ki-67, chemotherapy,
Introduction: Aggressive neuroendocrine neoplasms (NEN) encompass both poorly differentiated carcinomas (NEC) and high grade neuroendocrine tumors (G3-NET) with a Ki-67 index >20%; WHO 2010.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: olsen i
Authors: Olsen I, Borbath I, Heetfeld M, Walter T, Barriuso J,
Keywords: neuroendocrine carcinoma, Ki-67, immunohistochemistry, treatment,
#776 Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 85 Patients
Introduction: Appendiceal Goblet cell carcinoids (GCC) exhibit neuroendocrine and adenocarcinoma features.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Olsen I, Holt N, Langer S, Federspiel B, Hasselby J,
Keywords: prognosis,
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETSConcerence (2011)
Presenting Author:
Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,
Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,